Search

Share:

The Internet site that you are about to view is an online educational resource intended
for medical professionals based in the United Kingdom. The site contains up-to-date
information on The Binding Site’s products, and may therefore contain information on
medical devices and other products or uses of those products that are not approved or
cleared in other countries or regions.
This site is not intended to promote off label use of any of The Binding Site’s
products. To obtain appropriate product information for your country of residence,
please contact your local distributor.

In 2012, Comenzo et al. [23]published consensus guidelines for the definition of organ involvement and response to treatment in AL amyloidosis. The guidelines are based on data from an international cohort of 816 patients from seven referral centres, for which haematological responses were assessed 3 and/or 6 months after initiation of first-line therapy. Haematological response categories were defined, as detailed in Table 28.2. There was a strong correlation between the haematological response category at 3 or 6 months and overall survival (Section 28.8). The haematological response criteria were subsequently validated in a prospective study of 374 patients [117], and have now been widely adopted and incorporated into national guidelines [24].

The definition of measurable disease by sFLC analysis was defined as a dFLC of >50 mg/L, and covers approximately 85% of newly diagnosed patients (Section 28.4). For the 15% of patients with unmeasurable sFLCs at baseline, standard criteria for response in MM are available (a monoclonal intact immunoglobulin concentration of >5 g/L is considered assessable for response, Chapter 25).